Stephan Rosenkranz
Overview
Explore the profile of Stephan Rosenkranz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
9733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skowasch D, Pausch C, Huscher D, Pittrow D, Wede J, Kreimendahl F, et al.
ESC Heart Fail
. 2025 Mar;
PMID: 40037846
Aims: Pulmonary arterial hypertension (PAH) is often diagnosed in elderly patients with comorbidities. Although initial monotherapy is recommended for these patients, the value of combination therapy remains unclear. Here, we...
2.
Kramer M, Rosenkranz S, Kramer T
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941652
Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure, often leading to right heart failure and poor prognosis. Depression, a common comorbidity in PH, significantly affects the quality of...
3.
Osborn R, Pelc D, Krogstad M, Rosenkranz S, Greven M
Sci Adv
. 2025 Feb;
11(7):eadt7770.
PMID: 39937894
The role of inhomegeneity in determining the properties of correlated electron systems is poorly understood because of the dearth of structural probes of disorder at the nanoscale. Advances in both...
4.
Braumann S, Macherey-Meyer S, Polzin A, Costard-Jackle A, Morbach C, Haring B, et al.
Circulation
. 2025 Feb;
PMID: 39937049
No abstract available.
5.
Luo Z, Zhao H, Cai W, Shahabfar S, Li J, Cai S, et al.
J Am Chem Soc
. 2025 Feb;
147(8):6753-6762.
PMID: 39932398
Low-dimensional materials with charge density waves (CDW) are attractive for their potential to exhibit superconductivity and nontrivial topological electronic features. Here we report the two-dimensional (2D) chalcogenide, BaSbTeS which acts...
6.
Hoeper M, Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Kopec G, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884760
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the...
7.
Ufnal M, Connolly K, Millegard M, Surkova E, Guazzi M, Bonderman D, et al.
ESC Heart Fail
. 2025 Jan;
PMID: 39829393
Aims: Despite receiving guideline-directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH-LHD) experience higher mortality and hospitalization rates than the general HF population....
8.
Gertz R, Lennartz S, Kaya K, Wawer Matos Reimer R, Pennig L, Kottlors J, et al.
Int J Cardiovasc Imaging
. 2024 Dec;
41(2):303-314.
PMID: 39720959
To evaluate dual-layer dual-energy computed tomography (dlDECT)-based characterization of thrombus composition for differentiation of acute pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH). This retrospective single center cohort study...
9.
Hoeper M, Rosenkranz S, Badesch D, Humbert M, Langleben D, McConnell J, et al.
Respir Med
. 2024 Dec;
236:107910.
PMID: 39667586
Background: Risk stratification is an essential part of evaluating disease severity in patients with pulmonary arterial hypertension (PAH). This study applied the 4-strata COMPERA 2.0 risk model to the Phase...
10.
Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Hoeper M, Humbert M, et al.
J Heart Lung Transplant
. 2024 Dec;
PMID: 39645016
Background: This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). Methods: Pooled data from PULSAR (N ...